To the Editor In their cohort study in JAMA Oncology, Hirsch et al1 found that cabozantinib had considerable intracranial activity and an acceptable safety profile in patients with renal cell carcinoma with brain metastases. These findings substantiate the superiority of cabozantinib for treatment of renal cell carcinoma with brain metastases. However, the conclusions should be critically interpreted and require more suggestions.
Zhao B, Ma W. Cabozantinib for Treatment of Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncol. 2022;8(5):783. doi:10.1001/jamaoncol.2022.0052
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.